Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Usana Health Sciences Inc

USNA NYSE Medicinal Chemicals & Botanical Products Financials FY2016–FY2025

Last close · Oct 23, 2026

$13.96

3.9%
Compare
Revenue Total sales reported in the income statement.
$925M
8.3% vs prior year
Operating margin Operating income as a share of revenue.
4.0%
3.7 pts
Net income Profit after all expenses, interest and tax.
$10.8M
74.4%
Free cash flow Cash from operations minus capital spending.
$8.5M
83.3%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap Last close times the latest diluted share count, so it is approximate.
$258M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On −$1.18 EPS (TTM)

What Usana Health Sciences Inc does

No business description yet.

Legal name
USANA HEALTH SCIENCES INC
Fiscal year ends
January 3, 2026
Latest annual report
10-K · Mar 16, 2026
Accession · CIK
0000896264-26-000021
0000896264

Revenue and margins

Usana Health Sciences Inc had $925M of revenue in fiscal 2025, up 8.3% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2016 to 2025, diluted EPS grew −19.3% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $8.5M in fiscal 2025, 0.9% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Usana Health Sciences Inc returned $27.5M to shareholders in fiscal 2025, 323% of free cash flow. The diluted share count fell 3.1%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Usana Health Sciences Inc can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $240M$288M$330M$182M$158M
Interest coverage 2,985.8x560.5x355.2x236.0x44.5x
Current ratio 2.3x2.7x3.5x2.0x2.2x
Quick ratio 1.7x2.2x3.0x1.5x1.4x
Total assets $578M$597M$633M$748M$743M
Total liabilities $183M$162M$136M$162M$157M
Shareholders' equity $395M$434M$497M$532M$533M
Net debt (− = net cash) —————

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Return on assets rose — ✕ ✓ ✕ ✓ ✓ ✕ ✕ ✕ ✕
Cash from operations exceeds net income ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Debt fell relative to assets — — — — — — — — — —
Current ratio rose — ✓ ✓ ✕ ✓ ✕ ✓ ✓ ✕ ✓
Share count didn't rise — ✓ ✓ ✓ ✓ ✓ ✓ ✕ ✓ ✓
Gross margin rose — ✓ ✓ ✕ ✕ ✓ ✕ ✓ ✓ ✕
Revenue rose relative to assets — ✕ ✓ ✕ ✕ ✓ ✕ ✕ ✕ ✓
F-score — / 36 / 88 / 84 / 86 / 87 / 85 / 85 / 85 / 86 / 8
Accruals ratio −7.8%−12.4%−4.8%−4.9%−6.2%−0.8%−5.9%−1.1%−2.7%−1.6%
Altman Z'' 8.118.489.628.528.768.528.8110.237.367.37

10 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $1.0B $1.0B $1.2B $1.1B $1.1B $1.2B $999M $921M $855M $925M
Gross profit $826M $868M $989M $873M $926M $969M $805M $744M $693M $724M
Research and development $8.8M $9.0M $10.2M $10.3M $10.6M $11.1M $11.6M $11.4M $11.6M $10.7M
Operating income $139M $133M $188M $146M $176M $170M $108M $93.1M $66.3M $37.4M
Interest expense $0.4M $0.0M $0.0M $0.1M $0.5M $0.1M $0.2M $0.3M $0.3M $0.8M
Pretax income $139M $135M $192M $150M $178M $171M $109M $102M $76.4M $41.5M
Income tax $38.5M $72.1M $65.3M $50.0M $53.3M $54.1M $39.3M $38.7M $34.3M $30.1M
Net income $100M $62.5M $126M $101M $125M $117M $69.4M $63.8M $42.0M $10.8M
Net income to common $100M $62.5M $126M $101M $125M $117M $69.4M $63.8M — —
Diluted EPS $3.99 $2.53 $5.12 $4.41 $5.86 $5.73 $3.59 $3.30 $2.19 $0.58
Diluted shares 0.03B 0.02B 0.02B 0.02B 0.02B 0.02B 0.02B 0.02B 0.02B 0.02B
Cash flow
Cash from operations $137M $124M $152M $127M $160M $121M $104M $70.6M $61.0M $22.3M
Capital expenditure $32.7M $13.2M $11.4M $16.6M $15.1M $12.8M $10.4M $14.5M $10.1M $13.8M
Free cash flow $104M $111M $141M $110M $145M $108M $93.5M $56.1M $50.9M $8.5M
Depreciation and amortization $13.5M $16.1M $16.8M $14.7M $13.7M $13.0M $13.4M $12.7M $14.5M $32.6M
Stock-based compensation $16.5M $15.5M $15.0M $15.5M $14.4M $14.3M $13.3M $14.6M $14.6M $13.8M
Acquisitions — — — — $0.0M $0.0M $6.5M $0.0M $203M $0.0M
Share buybacks $64.6M $50.0M $105M $150M $57.0M $178M $25.4M $11.6M $9.4M $27.5M
Dividends and buybacks $64.6M $50.0M $105M $150M $57.0M $178M $25.4M $11.6M $9.4M $27.5M
Balance sheet
Cash and short-term investments $176M $247M $214M $235M $312M $240M $288M $330M $182M $158M
Current assets $278M $340M $392M $329M $425M $365M $384M $418M $279M $288M
Current liabilities $138M $141M $149M $136M $168M $161M $144M $119M $140M $129M
Inventory $64.8M $62.9M $81.9M $68.9M $90.2M $98.3M $67.1M $61.5M $69.7M $103M
Property and equipment, net $101M $103M $92.0M $95.2M $100M $102M $97.8M $99.8M $94.6M $94.4M
Goodwill $16.7M $17.4M $16.8M $16.6M $17.4M $17.7M $17.4M $17.1M $144M $138M
Intangible assets $34.3M $35.2M $31.8M $29.8M $30.8M $30.4M $32.4M $29.9M $152M $133M
Total assets $471M $519M $554M $517M $641M $578M $597M $633M $748M $743M
Total liabilities $145M $156M $163M $165M $199M $183M $162M $136M $162M $157M
Shareholders' equity $325M $363M $391M $352M $442M $395M $434M $497M $532M $533M
Margins
Gross margin 82.1% 82.9% 83.1% 82.3% 81.6% 81.6% 80.6% 80.8% 81.1% 78.3%
Operating margin 13.8% 12.7% 15.8% 13.8% 15.6% 14.3% 10.8% 10.1% 7.8% 4.0%
EBITDA margin 15.1% 14.2% 17.3% 15.2% 16.8% 15.4% 12.1% 11.5% 9.5% 7.6%
Net margin 9.9% 6.0% 10.6% 9.5% 11.0% 9.8% 6.9% 6.9% 4.9% 1.2%
FCF margin 10.4% 10.6% 11.8% 10.4% 12.8% 9.1% 9.4% 6.1% 6.0% 0.9%
Returns
Return on capital employed 41.7% 35.0% 46.4% 38.4% 37.3% 40.8% 23.8% 18.1% 10.9% 6.1%
Return on equity 30.8% 18.2% 33.5% 27.1% 31.4% 27.8% 16.7% 13.7% 8.2% 2.0%
Return on assets 21.3% 12.6% 23.5% 18.8% 21.5% 19.1% 11.8% 10.4% 6.1% 1.4%
Return on tangible equity 36.5% 20.1% 36.9% 32.9% 31.7% 33.6% 18.0% 14.2% 17.8% 4.1%
Growth
Revenue growth — 4.1% 13.6% −10.8% 7.0% 4.6% −15.8% −7.8% −7.2% 8.3%
Net income growth — −37.5% 101.8% −20.4% 24.0% −6.5% −40.5% −8.0% −34.1% −74.4%
EPS growth — −36.6% 102.4% −13.9% 32.9% −2.2% −37.3% −8.1% −33.6% −73.5%
FCF growth — 6.1% 27.3% −21.7% 31.9% −25.4% −13.8% −40.0% −9.3% −83.3%
Share count change — −1.4% −0.3% −7.4% −6.8% −4.3% −5.1% 0.2% −0.9% −3.1%
Financial health
Interest coverage 312.2x 2,880.5x 5,232.0x 2,215.0x 348.1x 2,985.8x 560.5x 355.2x 236.0x 44.5x
Current ratio 2.0x 2.4x 2.6x 2.4x 2.5x 2.3x 2.7x 3.5x 2.0x 2.2x
Quick ratio 1.5x 2.0x 2.1x 1.9x 2.0x 1.7x 2.2x 3.0x 1.5x 1.4x
Capital allocation
Capex / revenue 3.3% 1.3% 1.0% 1.6% 1.3% 1.1% 1.0% 1.6% 1.2% 1.5%
Stock comp / revenue 1.6% 1.5% 1.3% 1.5% 1.3% 1.2% 1.3% 1.6% 1.7% 1.5%
Payouts / FCF 62.0% 45.2% 74.9% 136.2% 39.2% 164.0% 27.1% 20.7% 18.5% 322.6%
Quality scores
Piotroski F-score — 6.0 8.0 4.0 6.0 7.0 5.0 5.0 5.0 6.0
Altman Z'' 8.1 8.5 9.6 8.5 8.8 8.5 8.8 10.2 7.4 7.4
Accruals ratio −7.8% −12.4% −4.8% −4.9% −6.2% −0.8% −5.9% −1.1% −2.7% −1.6%

Source: SEC EDGAR XBRL filings (CIK 0000896264). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open